{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiauijn3bquin43rgj766r6w6hglaulvbtgk75i4t65hwgq5zlqyh4",
    "uri": "at://did:plc:7nuyhqvd4a6xquezhjhvregv/app.bsky.feed.post/3mnznicste332"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiffl6nslzlu3rbvh6zle7pkcjyh7tfv4uyqns7pznu4ejftugxzl4"
    },
    "mimeType": "image/jpeg",
    "size": 739156
  },
  "path": "/2026/06/11/well/measles-treatments-drug-vaccine.html",
  "publishedAt": "2026-06-11T15:00:03.000Z",
  "site": "https://www.nytimes.com",
  "tags": [
    "Measles",
    "Disease Rates",
    "Vaccination and Immunization",
    "Immune System",
    "Biotechnology and Bioengineering",
    "Drugs (Pharmaceuticals)"
  ],
  "textContent": "As vaccination rates decline, biotech companies see a potential new market for measles drugs.",
  "title": "With Measles Roaring Back, the Search for a Drug is On"
}